Bristol Myers Squibb Company (NYSE:BMY) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Bristol Myers Squibb Company (NYSE:BMY) have been given a consensus recommendation of “Moderate Buy” by the twenty-five analysts that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, eleven have given a hold recommendation, twelve have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $66.0556.

BMY has been the subject of several research reports. Royal Bank Of Canada lifted their target price on Bristol Myers Squibb from $60.00 to $64.00 and gave the company a “sector perform” rating in a research note on Friday, July 31st. UBS Group lowered Bristol Myers Squibb from a “buy” rating to a “neutral” rating in a research note on Wednesday. JPMorgan Chase & Co. raised their price target on Bristol Myers Squibb from $67.00 to $73.00 and gave the company an “overweight” rating in a report on Friday, July 31st. Guggenheim reissued a “buy” rating and set a $75.00 price objective (up from $72.00) on shares of Bristol Myers Squibb in a report on Friday, July 31st. Finally, Roth Capital assumed coverage on shares of Bristol Myers Squibb in a research report on Wednesday. They set a “buy” rating and a $75.00 target price on the stock.

Bristol Myers Squibb Price Performance

Shares of BMY stock opened at $63.73 on Thursday. Bristol Myers Squibb has a 1 year low of $42.52 and a 1 year high of $68.10. The company has a current ratio of 1.53, a quick ratio of 1.38 and a debt-to-equity ratio of 1.89. The firm’s 50 day moving average is $58.41 and its 200-day moving average is $58.53. The firm has a market capitalization of $130.18 billion, a price-to-earnings ratio of 14.04, a PEG ratio of 0.17 and a beta of 0.22.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.60 by $0.44. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The business had revenue of $12.97 billion during the quarter, compared to analyst estimates of $11.74 billion. During the same quarter last year, the business posted $1.46 earnings per share. Bristol Myers Squibb’s revenue for the quarter was up 5.7% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Sell-side analysts forecast that Bristol Myers Squibb will post 6.97 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 2nd were paid a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.0%. The ex-dividend date of this dividend was Thursday, July 2nd. Bristol Myers Squibb’s payout ratio is 55.51%.

Key Stories Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Argus upgraded Bristol Myers Squibb (BMY) from “hold” to “buy” and set a $75 price target, implying meaningful upside from the stock’s recent level. The upgrade provides support for the investment case despite the merger speculation fading. Argus upgrade report
• Neutral Sentiment: Berenberg maintained a “hold” rating on BMY, indicating that some analysts remain cautious even after the stock reached a new 52-week high. Berenberg maintains hold rating
• Neutral Sentiment: BMY’s recent rally and 52-week-high performance have prompted investors to evaluate whether additional gains are justified by the company’s fundamentals and valuation, rather than by potential merger activity. BMY 52-week-high analysis
• Negative Sentiment: Reuters reported that a senior source denied any ongoing merger discussions between AstraZeneca and Bristol Myers Squibb. The news reverses earlier reports that had fueled expectations for a transformative deal, likely pressuring BMY as investors remove any merger premium from the shares. Reuters report denying AstraZeneca-Bristol Myers discussions

Hedge Funds Weigh In On Bristol Myers Squibb

Hedge funds and other institutional investors have recently bought and sold shares of the business. Swiss RE Ltd. bought a new position in shares of Bristol Myers Squibb in the 4th quarter worth $25,000. Darwin Wealth Management LLC bought a new stake in Bristol Myers Squibb in the second quarter valued at about $25,000. Physician Wealth Advisors Inc. lifted its stake in Bristol Myers Squibb by 73.5% in the fourth quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 202 shares during the period. Bayban bought a new position in Bristol Myers Squibb during the fourth quarter worth about $31,000. Finally, EQ Wealth Advisors LLC acquired a new position in shares of Bristol Myers Squibb during the 4th quarter worth about $32,000. 76.41% of the stock is owned by institutional investors.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.